Syndax Pharmaceuticals (SNDX) –
-
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
-
Syndax Pharmaceuticals (SNDX) Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
-
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Form ARS Syndax Pharmaceuticals For: Dec 31
-
Form DEFA14A Syndax Pharmaceuticals
-
Form DEF 14A Syndax Pharmaceuticals For: Mar 27
-
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
-
Zymeworks (ZYME) Appoints Neil Gallagher to its Board
-
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
-
Syndax Pharmaceuticals (SNDX) Granted FDA Priority Review of NDA for Revumenib
-
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
-
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at JPMorgan
-
Form 8-K Syndax Pharmaceuticals For: Mar 15
-
Syndax Pharmaceuticals (SNDX) names Steven Closter as Chief Commercial Officer
-
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
-
Syndax Pharmaceuticals (SNDX) spreader active in April 17.50 puts, April 22.50 puts and April 30 calls
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Syndax Pharmaceuticals (SNDX) Files Mixed Shelf
-
Form S-3ASR Syndax Pharmaceuticals
-
Form S-8 Syndax Pharmaceuticals
-
Form 10-K Syndax Pharmaceuticals For: Dec 31
-
Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c
-
Incyte (INCY) Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
-
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
-
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
-
Form 8-K Syndax Pharmaceuticals For: Feb 27
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
-
Form SC 13G Syndax Pharmaceuticals Filed by: Kynam Capital Management, LP
-
Form SC 13G/A Syndax Pharmaceuticals Filed by: Point72 Asset Management, L.P.
-
Form SC 13G/A Syndax Pharmaceuticals Filed by: Avidity Partners Management LP
-
Form SC 13G Syndax Pharmaceuticals Filed by: VANGUARD GROUP INC
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Goldan Keith A.
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Gallagher Neil
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Jarrett Jennifer
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Metzger Michael A
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Huber Martin H. Jr.
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Katkin Keith
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Podlesak Dennis
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Legault Pierre
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Morrison Briggs
-
Form 4 Syndax Pharmaceuticals For: Feb 07 Filed by: Meury William
-
Form SC 13G/A Syndax Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Syndax Announces Participation at Two Upcoming Investor Conferences
-
Scotiabank Downgrades Syndax Pharmaceuticals (SNDX) to Sector Perform
-
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock Inc.
-
Form SC 13G/A Syndax Pharmaceuticals Filed by: STATE STREET CORP
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Back to SNDX Stock Lookup
